» Articles » PMID: 15480434

Expression and Co-expression of the Members of the Epidermal Growth Factor Receptor (EGFR) Family in Invasive Breast Carcinoma

Overview
Journal Br J Cancer
Specialty Oncology
Date 2004 Oct 14
PMID 15480434
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

The epidermal growth factor receptor (EGFR) family plays an important role in breast carcinogenesis. Much interest has been focused recently on its members because of their potential role as prognostic indicators in breast cancer and their involvement in cancer therapy. We have evaluated more than 1500 cases of invasive breast carcinoma immunohistochemically using tissue microarray technology to examine the expression of EGFR family receptor proteins. We have found that 20.1 and 31.8% of cases were positive for EGFR and c-erbB-2, respectively, and 45 and 45.1% of tumours overexpressed for c-erbB-3 and c-erbB-4, respectively. The expression of either EGFR or c-erbB-2 was associated with other bad prognostic features and with poor outcome. Neither c-erbB-3 nor c-erbB-4 had any association with survival. c-erbB-2 had an independent prognostic effect on overall and disease-free survival (DFS) in all cases, as well as in the subset of breast carcinoma patients with nodal metastases. Several hetero- and homodimeric combinations have been reported between the EGFR members. Those dimers can evoke diverse signal transduction pathways with variable cellular responses. We stratified cases according to their co-expression of receptors into distinct groups with different receptor-positive combinations. Patients whose tumours co-expressed c-erbB-2 and c-erbB-3, as well as those whose tumours co-expressed EGFR, c-erbB-2 and c-erbB-4 showed an unfavourable outcome compared with other groups, while combined c-erbB-3 and c-erbB-4 expression was associated with a better outcome. In cases showing expression of one family member only (homodimers), we found a significant association between c-erbB-4 homodimer-expressing tumours and better DFS. In contrast, patients with c-erbB-2 homodimer-expressing tumours had a significant poorer DFS compared with other cases. These data imply that the combined profile expression patterns of the four receptor family members together provide more accurate information on the tumour behaviour than studying the expression of each receptor individually.

Citing Articles

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer.

Jeong Y, Kim H, You D, Cho S, Yoon S, Kim S Cells. 2025; 14(1.

PMID: 39791720 PMC: 11719728. DOI: 10.3390/cells14010019.


Investigating the Co-Expression Rate of HER2 and HER3 Biomarkers in Cancer Patients: A Systematic Review and Meta-Analysis.

Makoui R, Fekri S, Ansari N, Makoui M Asian Pac J Cancer Prev. 2024; 25(9):2979-2990.

PMID: 39342574 PMC: 11700328. DOI: 10.31557/APJCP.2024.25.9.2979.


Role and mechanism of in promoting malignant behaviors in gastric cancer.

Zhang S, Luo Q, Xiao L, Yang F, Zhu J, Chen X Front Pharmacol. 2024; 15:1341039.

PMID: 38711992 PMC: 11070777. DOI: 10.3389/fphar.2024.1341039.


The expression of high mobility group protein 3 () in breast cancer with emphasis on its role in lymphovascular invasion.

Aljohani A, Alsaeed S, Toss M, Raafat S, Green A, Rakha E Am J Cancer Res. 2023; 13(11):5334-5351.

PMID: 38058796 PMC: 10695817.


Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H Mab-77-mG -f.

Tanaka T, Suzuki H, Ohishi T, Kaneko M, Kato Y Cancer Sci. 2023; 115(1):298-309.

PMID: 37942574 PMC: 10823288. DOI: 10.1111/cas.16008.


References
1.
Naidu R, Yadav M, Nair S, Kutty M . Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer. 1998; 78(10):1385-90. PMC: 2063171. DOI: 10.1038/bjc.1998.689. View

2.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

3.
Suo Z, Emilsen E, Tveit K, Nesland J . Type 1 protein tyrosine kinases in benign and malignant breast lesions. Histopathology. 1998; 33(6):514-21. DOI: 10.1046/j.1365-2559.1998.00498.x. View

4.
Gullick W, Srinivasan R . The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat. 1999; 52(1-3):43-53. DOI: 10.1023/a:1006107016969. View

5.
Walker R, Dearing S . Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat. 1999; 53(2):167-76. DOI: 10.1023/a:1006194700667. View